bullish
Bristol Myers Squib – Reaffirming Its View on Celgene Corp
The management of Bristol Myers Squibb Co (BMY US) reiterated its optimistic view regarding the acquisition of Celgene Corp (CELG US) on its Q4-18...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
ANTYA Investments
Investing That Empowers You
Price Chart(Sign Up to Access)
- Bristol Myers Squib & Celgene–Starboard Objections Addressed Today- Successful Deal Closure Probable07 Mar 2019
- Bristol-Myers Beats the Drum for Celgene in 4Q18 Earnings Call25 Jan 2019
- Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated18 Jan 2019
- Celgene Acquisition by Bristol-Myers Squibb: A Call to Arbs13 Jan 2019
x